ITGAX and neoplasm: Relative to the control and monotherapies, the combination therapy increased the numbers of tumor-infiltrating CD3+ T, CD8+ T, activated CD8+ T (CD25+/CD69+ CD8+), effective memory CD8+ T (Tem) (CD44+ CD62L− CD8+), Ki67+ CD8+ T, IFN-γ+ CD8+ T, Granzyme-B+ CD8+ T, NK (CD3− CD49b+), Ki67+ NK, IFN-γ+ NK, Granzyme-B+ NK, TNF-α+ NK, DC (CD11c+ MHC-II+), CD80+ DC, CD86+ DC, M1-like macrophage (MHC-II+ CD206− CD11b+ F4/80+) (Fig. 5e–v).